Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ranbaxy OTC antihistamine

This article was originally published in The Tan Sheet

Executive Summary

The India-based firm receives FDA approval to manufacture and commercialize 10 mg tablets of its bioequivalent to OTC Claritin Reditabs (loratadine), Ranbaxy subsidiary Ohm Laboratories says April 12. Loratadine provided in orally disintegrating tablets has annual sales of $58.7 million, according to North Brunswick, N.J.-based Ohm, which sells and distributes generic and private-label OTC products in the U.S. Ranbaxy says the product will be distributed by Ohm and will be available in U.S. markets in late June this year. Schering-Plough filed for a Claritin switch in March 2002 and received an approval in November that year (1"The Tan Sheet" Dec. 9, 2002, p. 4)...

You may also be interested in...

Import Alert On Drugs From Ranbaxy’s Plants Includes OTC Product

India's largest drug maker, Ranbaxy, faces a hurdle to growing its U.S. business with FDA's ban on imports of some of its products, including an OTC drug

Schering OTC Claritin Coupons Appearing In Newspapers Dec. 15

Schering-Plough is offering consumers free samples of Claritin through a new Web site that became operational shortly after the drug's OTC approval

Pink Sheet Podcast: Woodcock To Be Acting US FDA Chief, Key Staff Depart, Political Donations Shift

Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts